title: Total-body irradiation--role and indications: results from the German Registry for Stem Cell Transplantation (DRST).
abstract: OBJECTIVE
  Total-body irradiation (TBI) is a key part of the conditioning regimen before hematopoietic stem cell transplantation (HSCT). The exact role of TBI as part of the conditioning regimen is largely unclear. In order to determine the relevance of TBI, the status of TBI utilization was analyzed on the basis of a nationwide registry.
  
  
  METHODS
  14,371 patients (1998-2002) documented in the German Stem Cell Transplantation Registry (DRST) were analyzed regarding TBI utilization prior to autologous or allogeneic transplantation, underlying disorder, type of donor, stem cell source, and size of the treatment center.
  
  
  RESULTS
  For autologous HSCT approximately 10% of the patients (873/8,167) received TBI, with chronic lymphocytic leukemia (CLL, approximately 80%, 171/214) and low-grade non-Hodgkin's lymphoma (l-NHL, approximately 35%, 330/929) being the most important disorders. In the allogeneic setting 50% of the patients (2,399/4,904) received TBI, with acute lymphocytic leukemia (ALL, 85%, 794/930), acute myeloid leukemia (AML, 45%, 662/1,487) and chronic myeloid leukemia (CML, 49%, 561/1,156) being the key indications. The type of donor, stem cell source and center size did not strongly influence the use of TBI.
  
  
  CONCLUSIONS
  TBI has only a limited role for the conditioning prior to autologous HCST. For allogeneic HSCT TBI is widely accepted with no major changes over the observation time. The use of TBI is generally accepted for ALL, whereas approximately half of the patients with CML or AML received TBI. Although a considerably large database was analyzed, no clear determinants for the use of TBI could be distinguished.
authors.affiliation: Department of Radiation Oncology, University of Tuebingen, Hoppe-Seyler-Strasse 3, 72076 Tuebingen, Germany.
authors.forename: Frank
authors.initials: F
authors.lastname: Heinzelmann
authors.forename: Helmut
authors.initials: H
authors.lastname: Ottinger
authors.forename: Carl-Heinz
authors.initials: CH
authors.lastname: Müller
authors.forename: Sandra
authors.initials: S
authors.lastname: Allgaier
authors.forename: Christoph
authors.initials: C
authors.lastname: Faul
authors.forename: Michael
authors.initials: M
authors.lastname: Bamberg
authors.forename: Claus
authors.initials: C
authors.lastname: Belka
mesh_terms: D000208:Acute Disease; D005858:Germany; D006650:Histocompatibility Testing; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000628:therapy; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy; D007951:Leukemia, Myeloid / Q000628:therapy; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000628:therapy; D012042:Registries; D033581:Stem Cell Transplantation; D014019:Tissue Donors; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous; D014916:Whole-Body Irradiation